Lacosamide Solution
Product Images NDC 72603-305

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 72603-305). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Lacosamide Fig1)

A bar graph titled 'Median Percent Reduction in Seizure Frequency per 28 days from Baseline to the Maintenance Phase by Dose' showing seizure reduction percentages for placebo and Lacosamide at various doses across three studies (Study 2, Study 3, and Study 4). The y-axis represents percent seizure reduction from baseline (0% to 45%), and bars display median percent reductions. Lacosamide doses (200, 400, 600 mg/day) consistently show higher seizure reduction compared to placebo, with statistical significance indicated for most doses.*

FDA Label Image

Figure 2 (Lacosamide Fig2)

A line graph showing the proportion of patients by responder rate for Lacosamide and placebo groups across studies 2, 3, and 4. The y-axis represents responder rate from worsening (-100%) to improvement (100%), and the x-axis shows percent of patients from 100% to 0%. Four lines represent placebo and Lacosamide doses of 200 mg/day, 400 mg/day, and 600 mg/day, illustrating their respective response distributions.*

FDA Label Image

Figure 3 (Lacosamide Fig3)

Kaplan-Meier survival analysis chart showing the time to second PGTC seizure for Lacosamide versus placebo in a modified full analysis study set. The graph plots the proportion of patients without seizure over time (days), comparing two groups indicated by solid and dashed lines. The chart also includes patient numbers at risk at various timepoints and statistical details such as p-value, hazard ratio, and confidence interval.*

FDA Label Image

Package Label-principal Display Panel (10 mg/mL Container (200mL))

Lacosamide Oral Solution, USP 10 mg/mL in a 200 mL bottle. The label notes it is for prescription use only and includes dosing, storage instructions, and a warning for phenylketonurics. The product is manufactured by Aurobindo Pharma Limited and labeled by NorthStar Rx LLC. The label also includes a barcode and medication guide information.*

FDA Label Image

Chemical Structure (Lacosamide Str)

Chemical structure of lacosamide, showing its molecular arrangement including a phenyl group and functional groups characteristic of the compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.